Stability testing of pharmaceutical products - comparison of stability testing guidelines

Current Pharmaceutical Analysis

Volumn 6, Issue 2, 2010, Pages 142-150

  Khan, Hamid ^a   Ali, Mushir ^a   Ahuja, Alka ^a   Ali, Javed ^a  

^a HAMDARD UNIVERSITY   (India)

Author keywords

International conference on harmonization; Pharmaceutical products; Stability guidelines; Stability testing; World health organization

Indexed keywords

ARTICLE; COMPARATIVE STUDY; DRUG FORMULATION; DRUG STABILITY; DRUG STORAGE; PHARMACOLOGIC STRESS TESTING; PRIORITY JOURNAL; WORLD HEALTH ORGANIZATION;

EID: 77952943815     PISSN: 15734129     EISSN: None     Source Type: Journal    
DOI: 10.2174/157341210791202627     Document Type: Article

References (65)

1. Yoshioka, S.; Stella, V.J. Stability of drugs and dosage forms, Kluwer Academic Publisher: New York, 2002.
2. Lachman, L. Physical and chemical stability of tablet dosage form. J. Pharm. Sci., 1965, 54(10), 1519-1526.
3. Tingstad, J.E. Physical stability of pharmaceuticals. J. Pharm. Sci., 1964, 53(8), 955-962.
4. Vadas, E.B. In Remington: The Science and Practice of Pharmacy; Gennaro, A.R., Ed.; Lippincott Williams and Wilkins: Philadelphia, 2000; Vol.1, pp. 986-994.
5. Martin, A.; Bustamante, P.; Chun, A.H.C. Physical Pharmacy, B.I. Waverly: New Delhi, 1999.
6. Lachman, L.; Deluca, P.; Akers, M.J. In Theory and Practice of Industrial Pharmacy; Lachman, L.; Lieberman, H.A.; Kanig, J.L., Ed.; Varghese Publishing House: Bombay, 1986; pp.760-795.
7. Pugh, J. In Pharmaceutics: The science of dosage form design; Aulton M.E., Ed.; Churchill Livingstone Harcourt: London, 2002; pp.101-112.
8. Subrahmaniam, C.V.S. Textbook of Physical Pharmaceutics, Vallabh Prakashan: New Delhi, 2001; pp. 51-65.
9. Connors, K.A.; Amidon, G.L.; Stella, V.J. Chemical stability of pharmaceuticals: A Hand book for pharmacists, Wiley-Interscience: New York, 1986.
10. Waterman, K.C.; Adami, R.C. Accelerated aging: Prediction of chemical stability of pharmaceuticals. Int. J. Pharm., 2005, 293(1-2), 101-125.
11. FDA, Guidance for Industry: Stability Testing of Drug Substances and Drug Products. Rockville, MD, 1998, Available at http://www.fda/cder/guidance/index.html
12. Carstensen, J.T.; Rhodes, C.T. Drug stability principles and practices, Marcel Dekker: New York, 2000.
13. Carstensen, J.T. Stability of solid and disperse systems. Drug Develop. Ind. Pharm., 1984, 10(8), 1277-1296.
14. Guillory, J.K.; Poust, R.I. In Modern Pharmaceutics; Banker, G.S.; Rhodes, C.T., Ed.; Marcel Dekker: New York, 2002; pp.139-163.
15. Mollica, J.A.; Ahuja, S.; Cohen, J. Stability of pharmaceuticals. J. Pharm. Sci., 1978, 67(4), 443-465.
16. Swarbrick, J.; Boylan, J.C. Encyclopedia of Pharmaceutical Technology, Marcel Dekker: New York, 1990.
17. Chafetz, L. Practical testing of solid state stability of pharmaceuticals. J. Pharm. Sci., 1992, 81(1), 107.
18. Yoshioka, S.; Carstensen, J.T. Rational storage conditions for accelerated testing of stability of solid pharmaceuticals. J. Pharm. Sci., 1990, 79(10), 943-944.
19. Garrett, E.R. Prediction of stability of drugs and pharmaceutical preparations. J. Pharm. Sci., 1962, 51(9), 811-833.
20. Monkhouse, D.C. Stability aspects of preformulation and formulation of solid pharmaceuticals. Drug Develop. Ind. Pharm., 1984, 10(8), 1373-1412.
21. Dukes, G.R. Stability programs for formulation studies. Drug Develop. Ind. Pharm., 1984, 10(8), 1413-1424.
22. Wong, A.W.; Datla, A. In Hand Book of Pharmaceutical Analysis by HPLC, Ahuja, S.; Dong, M.W., Ed.; Elsevier Academic Press: San Diego, 2005, pp. 335-358.
23. Branch, S.K., Guidelines from the International Conference on Harmonization. J. Pharm. Biomed. Anal., 2005, 38(5), 798-805.
24. ICH, Guidance for Industry: Stability testing of New Drug Substances and Products ICH Q1A(R2), 2003, Available at www.fda.gov/cber/gdlns/ichsta.pdf
25. WHO Guidelines for stability testing of pharmaceutical products containing well established drug substances in conventional dosage forms, 2006, Available at http://www.who.int/medicines/publi cations/ pharmprep/TRS_937.pdf
26. WHO Guidelines for stability testing of active pharmaceutical ingredients and finished pharmaceutical products, 2009, Available at http://www.who.int/medicines/publications/pharmprep/PDF_TR S953_WEB.pdf
27. Specification: Test procedures and acceptance criteria for new drug substances and new drug products: ICH Q6A, 2000, Available at http://www.ich.org/LOB/media/media430.pdf
28. Chandran S.; Singh R.S.P. Comparison of various International guidelines for analytical method validation. Pharmazie, 2007, 62(1), 4-14.
29. Validation of analytical procedures: text and methodology ICH Q2 (R1), 2003, Available at http://www.ich.org/LOB/media/media417. pdf
30. Singh, S.; Bakshi, M. Development of stability-indicating assay methods. J. Pharm. Biomed. Anal; 2002, 28(6), 1011-1040.
31. Rahman, N.; Azmi, S. N. H.; Wu, H. N. Importance of impurity analysis in pharmaceutical products. Accred. Qual. Assur.; 2006, 11(2), 69-74.
32. Ahuja, S. Impurities evaluation of pharmaceuticals, Marcel Dek-ker: New York, 2006.
33. Ahuja, S.; Scypinski, S. Hand Book of Modern Pharmaceutical Analysis, Harcourt Science and Technology: San Diego, 2001.
34. Dong, M.W.; Passalacqua, P.V.; Choudhary, D.R. Liquid chroma-tographic considerations for high sensitivity impurity and stability testing of pharmaceuticals. J. Liq. Chromatogr. Related Technol., 1990, 13(11), 2135-2160.
35. WHO Guidelines for stability testing of pharmaceutical products containing well established drug substances in conventional dosage forms, 1996, Available at http://www.who.int/medicines/publi cations/pharmprep/TRS_863.pdf
36. Singh, S.; Bakshi, M. Guidance on conduct of stress tests to determine inherent stability of drugs. Pharm. Technol., 2000, 24, 1-14.
37. Reynolds, D.W. Available guidance and best practices for conducting forced degradation studies. Pharm. Technol., 2002, 26(2), 48-56.
38. Alsante, K. M.; Martin, L.; Baertschi, S.W. A stress testing benchmarking study. Pharm. Technol., 2003, 27(2), 60-72.
39. Rourick, R.A.; Volk, K.J.; Klohr S.E.; Kerns E.H.; Lee, M.S. Predictive strategy for the rapid structure elucidation of drug de-gradants. J. Pharm. Biomed. Anal., 1996, 14(12), 1743-1752.
40. Photo stability testing of new drug substances and products ICH Q1B, 1996, Available at http://www.ich.org/LOB/media/media412. pdf
41. Sager, N.; Baum, R.; Wolters, R.; Layloff, T. Photostability testing of pharmaceutical products. Pharmacopoeial Forum, 1998, 24(3), 6331-6333.
42. Dean, D.A. Stability aspects of packaging. Drug Develop. Ind. Pharm., 1984, 10(8), 1463-1495.
43. Allinson, J.G.; Dansereau, R.J.; Sakr, A. The effects of packaging on the stability of a moisture sensitive compound. Int. J. Pharm., 2001, 221(2), 49-56.
44. International Conference on Harmonization. ICH Q1E: Evaluation for stability data, 2003, Available at http://www.ich.org/LOB/me-dia/me dia415.pdf
45. WHO Guidelines for registration of fixed-dose combination medicinal products. 2005, Available at http://www.who.int/medicines/publications/pharmprep/TRS_937.pdf
46. Zahl, M. A risk based approach to establish stability testing conditions for tropical countries. J. Pharm. Sci., 2006, 95(5), 946-965.
47. Haynes, J.D. Worldwide virtual temperatures for product stability testing. J. Pharm. Sci., 1971, 60(6), 927-929.
48. Bott, R. F.; Oliveira, W. P. Storage conditions for stability testing of pharmaceuticals in hot and humid regions. Drug Develop. Ind. Pharm., 2007, 33(4), 393-401.
49. Kommanaboyina, B.; Rhodes, C.T. Trends in stability testing with emphasis on stability during distribution and storage. Drug Develop. Ind. Pharm., 1999, 25(7), 857-868.
50. Lin, T.D.; Chen, C.W. Overview of stability study designs. J. Bio-pharm. Statist., 2003, 13(3), 337-354.
51. Paranjothy, K.L.K; Agarwal, P.K. Stability testing of pharmaceuticals. Indian Drugs, 1980, 17(4), 114-119.
52. Mathews, B.R. Regulatory aspects of stability testing in Europe. Drug Develop. Ind. Pharm., 1999, 25(7), 831-856.
53. Kaminski, E.E. Stability programs for marketed batches. Drug Develop. Ind. Pharm., 1984, 10(8), 1433-1448.
54. Fairweather, W.; Lin, T.D.; Kelly, R. Regulatory, design and analysis aspects of complex stability studies. J. Pharm. Sci., 1995, 84(11), 1322-1326.
55. Chow, S.C.; Liu, J.P. Statistical design and analysis in pharmaceutical science, Marcel Dekker: New York, 1995.
56. Rhodes, C.T. An overview of kinetics for the evaluation of the stability of pharmaceutical systems. Drug Develop. Ind. Pharm., 1984, 10(8), 1163-1174.
57. Grimm, W. Storage conditions for the most important market for drug products including EU, Japan and the USA. Drug Develop. Ind. Pharm., 1993, 19(20), 2795-2830.
58. Young, W.R. Accelerated temperature pharmaceutical product stability determinations. Drug Develop. Ind. Pharm. 1990, 16(4), 551-569.
59. Grimm, W. Extension of ICH Tripartite Guideline for stability testing of new drug substances and products to countries of climatic zones III and IV. Drug Develop. Ind. Pharm., 1998, 24(4), 313-325.
60. ASEAN Guidelines on stability study of drug product, 2005, Available at http://www.hsa.gov.sg/publish/etc/medialib/hsa_li-brary/health_products_regulation/western_medicines/files_guidelin es
61. Singh, S.; Kumar, V. Recent developments on long term stability test conditions. The Pharma Review, 2006, 4(24), 61-68.
62. Huynh-Ba, K. Hand book of stability testing in pharmaceutical development, Springer: New York, 2008.
63. Simon, P.; Veverka, M.; Okuliar, New screening method for the determination of stability of pharmaceuticals, Int. J. Pharm., 2004, 270(2), 21-26.
64. Grimm, W. Stability testing in industry for worldwide marketing, Drug Develop. Ind. Pharm., 1986, 12(8), 1259-1292.
65. Regional guidelines on stability testing of active substances and pharmaceutical products for the WHO Eastern Mediterranean Region, 2006, Available at http:// www.who.emro.int/edb/media/pdf/ EMRC5312En.pdf.